REFERENCES
1. Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr 2010;2010:113-6.
2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-65.
3. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015;1:888-96.
4. Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993;328:1587-91.
5. Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst 2015;107:djv263.
6. USA Life Expectancy. USA Causes of death by age and gender. Available from: https://www.worldlifeexpectancy.com/usa-cause-of-death-by-age-and-gender. [Last accessed on 20 Mar 2019].
7. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-7.
8. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-7.
9. Ho A, Goenka A, Ishill N, Van Zee K, McLane A, et al. The effect of age in the outcome and treatment of older women with ductal carcinoma in situ. Breast 2011;20:71-7.
10. Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol 2011;18:125-33.
11. Gradishar WJ, Anderson BO, Aft R, Balassanian R, Blair SL, et al. NCCN guidelines: breast cancer, version 1.2018. National Comprehensive Cancer Network, Inc.; 2018.
12. Older Americans 2016: Key Indicators of Well-Being. Federal Interagency Forum on Aging-Related Statistics. Washington, DC: U.S. Government Printing Office; 2016.
13. Arias E, Heron M, Xu JQ. United States life tables, 2014. National Vital Statistics Reports. Hyattsville, MD: Center for Disease Control; 2017.
14. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:1311-21.
15. Wong ML, McMurry TL, Schumacher JR, Hu CY, Stukenborg GJ, et al. Comorbidity assessment in the national cancer database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03). J Oncol Pract 2018;14:e631-43.
16. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170-8.
17. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
18. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-8.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
21. Yurkovich M, Avina-Zubieta JA, Thomas J, Gorenchtein M, Lacaille D. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol 2015;68:3-14.
22. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA 2012;307:182-92.
23. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, et al. Management of elderly patients with breast cancer: updated recommendations of the international society of geriatric oncology (SIOG) and european society of breast cancer specialists (EUSOMA). Lancet Oncol 2012;13:e148-60.
24. Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, et al. Functional status and survival after breast cancer surgery in nursing home residents. JAMA Surg 2018; doi: 10.1001/jamasurg.2018.2736.
25. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299-309.
26. Mallin K, Palis BE, Watroba N, Stewart AK, Walczak D, et al. Completeness of American cancer registry treatment data: implications for quality of care research. J Am Coll Surg 2013;216:428-37.
27. Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol) 2015;27:6-8.
28. Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer 2015;51:1497-510.
